Sekisui Diagnostics Metrix COVID/Flu Test

Sekisui Diagnostics has launched the Metrix COVID/Flu Test for use at the point of care and at home on the Metrix Molecular Platform. The molecular test, which returns results in 20 minutes, qualitatively detects and differentiates between RNA from SARS-CoV-2, influenza A, and influenza B from anterior nares swab samples. Sekisui inked an exclusive distribution agreement with Aptitude Medical Systems last year to sell the Aptitude Metrix COVID-19 test in the US. Now that Aptitude has received clearance from the US Food and Drug Administration for the combination test, Sekisui will also offer the combination test.